Company Overview and News

0
Redzone Announces the Receipt of its First Phase Exploration Permit

2018-06-13 globenewswire
VANCOUVER, British Columbia, June 13, 2018 (GLOBE NEWSWIRE) -- RedZone Resources Ltd. (TSXV:REZ) (Frankfurt:REZ) (OTCBB:REZZF) (“the Company” or “RedZone”) is pleased to announce the receipt of its first stage exploration permit, which will allow for trenching and sampling of its Arizona based Fortner Boyd lithium exploration property. The trenching program is expected to begin within two weeks, under the supervision and guidance of Jean-Philippe Paiement.
NMX REZ NMKEF

51
Resource Sector Digest: Sandstorm Gold And The Beauty Of Depletion

2018-06-05 seekingalpha
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
HRT MGG HRTFF MMRGF GFI.WI FNV NEM NMKEF RSG PRB RNX RNKLF KGC NMX RMGGF FQVLF AEM MACIF AG FQM GFIOF NDM WPM RPM FR SAND FNV.WT.A SSL GPL SDDXF ALO PROBF K RPMGD WHGOF RPMGF SNXZF ORG RGLD RNX.WT RMGGY GFI PGLC CANWF FNV RGL

7
Nemaska Lithium Welcomes New Directors

2018-06-01 globenewswire
QUEBEC CITY, June 01, 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (“Nemaska Lithium” or the “Corporation”) (TSX:NMX) (OTCQX:NMKEF) (FRANKFURT:N0T) is pleased to announce that, in connection with the completion of its project financing structure announced on May 30, 2018 and in accordance with terms of investment agreements with Ressources Québec (“RQ”) and SoftBank Group Corp. (“SoftBank”), its Board of Directors welcomes two new directors:
SWYDF MGPHF NMX LLG 9984 SFTBF TXTW SWY IAG SFTBY NMKEF

7
Nemaska Lithium accueille de nouveaux administrateurs

2018-06-01 globenewswire
QUÉBEC, 01 juin 2018 (GLOBE NEWSWIRE) -- Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») (TSX:NMX) (OTCQX:NMKEF) (FRANCFORT:N0T) est heureuse d’annoncer que, dans le cadre de la clôture de sa structure de financement de projet et conformément aux dispositions des ententes d’investissement avec Ressources Québec (« RQ ») et SoftBank Group Corp. (« SoftBank »), son conseil d’administration accueille deux nouveaux membres:
SWYDF MGPHF NMX LLG 9984 SFTBF SWY IAG SFTBY NMKEF

1
Nemaska Lithium Finally Out Of The Gate

2018-06-01 seekingalpha
Forecastannualized operating cash flow, and free cash flow (FCF) in first full year ofcommercial operation of US$293.7M.
NMX NMKEF PFS

28
CANADA STOCKS-TSX edges higher, powered by gains in energy stocks

2018-06-01 reuters
June 1 (Reuters) - Canada’s main stock index edged higher on Friday as gains in shares of energy companies more than offset losses in the heavyweight financials index.
SRHIF NGD NGDAF BCB DRGDF NGD NMKEF SU RNX RNX.WT COT RNKLF DGC NMX LB SU

35
Lithium Investing: Production Remains Concentrated Despite Significant Rise In Exploration Activity

2018-05-31 seekingalpha
A tidal wave of new junior exploration companies have entered the lithium market over the past 2 years; very few of these companies have delivered meaningful new volumes of chemicals.
ALB TYHOF LACDF NMKEF JODRF GALXF GXY AVLIF NMX 8015 OROCF LAC

0
CANADA STOCKS-TSX flat after U.S. tariffs on Canada steel, aluminum

2018-05-31 reuters
May 31 (Reuters) - Canada’s main stock index was little changed on Thursday after news of U.S. tariffs on aluminum and steel imports from Canada, Mexico and the European Union.
NMX SPB SUUIF NMKEF

21
PRESS DIGEST-Canada - May 31

2018-05-31 reuters
May 31 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
RDS.B RDS.A NMX RYDBF RDSB RDSA RYDAF NMKEF

2
Nemaska Lithium Completes Its CAD 1.1 Billion Financing Package

2018-05-30 globenewswire
Public Offering, Contemporaneous Private Placement, Bond Issue and SoftBank Private Placement Escrow Release complete comprehensive package that attracted investors from around the world
NMX 9984 SFTBF TXTW SFTBY NMKEF

2
Nemaska Lithium complète sa structure de financement de 1,1 milliard de dollars canadiens

2018-05-30 globenewswire
Le produit du Placement public, du Placement privé concomitant, du Placement d’obligations et du Placement privé Softbank complète le montage auquel des investisseurs du monde entier ont participé
NMX 9984 SFTBF SFTBY NMKEF

0
Evolving Gold Identifies Two Priority Exploration Targets on the Nicobi Project

2018-05-29 globenewswire
VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) -- Evolving Gold Corp. (CSE:EVG) (FSE:EV7) (OTCB:EVOGF) (the “Company”) is pleased to report that it has received complete analytical results of its most recent Nicobi Project geochemical sampling program, which was conducted on the property in the summer of 2017. It included a total of 12 rock samples and 43 till samples. A small field program conducted in 2016 had revealed anomalous gold and base metals in a contiguous series of 11 till samples taken alongside a logging road.
EVOGF NMX EVOGD NMKEF

38
Lithium Investment: Balancing Battery Demand Against Innovative Production And Supply

2018-05-29 seekingalpha
So much so, that many users are jumping in with investment dollars to stimulate and foster growth.
PLS PCRFY PILBF ALB LTUM FTI.WI TYHOF TOP FMC LACDF NMKEF ENRT AVLIF NMX 8015 RHHNF OROCF MLNLF LAC

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...